Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Whyte

Showing results (311-320 of 344) with videos related to

Pageof 35
Sort By:
Clinical Pharmacokinetics|May 15, 2015
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PDSimon J C Davies, Benoit H Mulsant, Alastair J Flint, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 4, 2008
Medical burden in late-life bipolar and major depressive disordersAriel G Gildengers, Ellen M Whyte, Rebecca A Drayer, et al.
Journal of Clinical Psychopharmacology|August 17, 2022
Placebo Effect in Randomized Trials of Major Depressive Disorder With Psychotic Features: A Systematic Review and Descriptive Meta-AnalysisArgyrios Perivolaris, Nicholas J Ainsworth, George S Alexopoulos, et al.
Cerebrovascular Diseases (Basel, Switzerland)|August 1, 2008
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patientsEllen M Whyte, Eric J Lenze, Meryl Butters, et al.
American Journal of Respiratory and Critical Care Medicine|August 10, 2000
Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphismsM Whyte, R Hubbard, R Meliconi, et al.
Journal of Affective Disorders|June 18, 2019
Health-related quality of life in remitted psychotic depression<sup>✰</sup>Kathleen S Bingham, Ellen M Whyte, Benoit H Mulsant, et al.
Journal of Affective Disorders|May 23, 2026
Effect of continuation treatment on health-related quality of life in remitted psychotic depressionRyma A Bendel, George S Alexopoulos, Patricia Marino, et al.
Psychiatry Research|September 19, 2024
Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trialRyma A Ihaddadene, George S Alexopoulos, Patricia Marino, et al.
Journal of Affective Disorders|April 5, 2025
Prediction of remission of pharmacologically treated psychotic depression: A machine learning approachEmily Carter, Samprit Banerjee, George S Alexopoulos, et al.
JAMA Psychiatry|February 27, 2020
Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical TrialAristotle N Voineskos, Benoit H Mulsant, Erin W Dickie, et al.
Pageof 35

Showing results (311-320 of 344) with videos related to

Sort By:
Pageof 35
Clinical Pharmacokinetics|May 15, 2015
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PDSimon J C Davies, Benoit H Mulsant, Alastair J Flint, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 4, 2008
Medical burden in late-life bipolar and major depressive disordersAriel G Gildengers, Ellen M Whyte, Rebecca A Drayer, et al.
Journal of Clinical Psychopharmacology|August 17, 2022
Placebo Effect in Randomized Trials of Major Depressive Disorder With Psychotic Features: A Systematic Review and Descriptive Meta-AnalysisArgyrios Perivolaris, Nicholas J Ainsworth, George S Alexopoulos, et al.
Cerebrovascular Diseases (Basel, Switzerland)|August 1, 2008
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patientsEllen M Whyte, Eric J Lenze, Meryl Butters, et al.
American Journal of Respiratory and Critical Care Medicine|August 10, 2000
Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphismsM Whyte, R Hubbard, R Meliconi, et al.
Journal of Affective Disorders|June 18, 2019
Health-related quality of life in remitted psychotic depression<sup>✰</sup>Kathleen S Bingham, Ellen M Whyte, Benoit H Mulsant, et al.
Journal of Affective Disorders|May 23, 2026
Effect of continuation treatment on health-related quality of life in remitted psychotic depressionRyma A Bendel, George S Alexopoulos, Patricia Marino, et al.
Psychiatry Research|September 19, 2024
Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trialRyma A Ihaddadene, George S Alexopoulos, Patricia Marino, et al.
Journal of Affective Disorders|April 5, 2025
Prediction of remission of pharmacologically treated psychotic depression: A machine learning approachEmily Carter, Samprit Banerjee, George S Alexopoulos, et al.
JAMA Psychiatry|February 27, 2020
Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical TrialAristotle N Voineskos, Benoit H Mulsant, Erin W Dickie, et al.
Pageof 35